Acurx Pharmaceuticals, Inc.ACXPNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank36
Year-over-Year Change
Year-over-year SG&A expense growth
Percentile
P36
Within normal range
vs 5Y Ago
-0.3x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | -8.39% |
| Q2 2025 | 12.58% |
| Q1 2025 | -20.77% |
| Q4 2024 | 20.53% |
| Q3 2024 | -29.33% |
| Q2 2024 | -18.63% |
| Q1 2024 | -11.00% |
| Q4 2023 | 79.61% |
| Q3 2023 | 3.34% |
| Q2 2023 | -9.46% |
| Q1 2023 | 3.26% |
| Q4 2022 | -6.29% |
| Q3 2022 | 14.14% |
| Q2 2022 | -7.69% |
| Q1 2022 | -3.12% |
| Q4 2021 | -45.64% |
| Q3 2021 | -11.58% |
| Q2 2021 | 187.57% |
| Q1 2021 | 117.53% |
| Q4 2020 | -2.91% |
| Q3 2020 | 27.69% |
| Q2 2020 | -13.75% |
| Q1 2020 | 0.00% |